Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

01-12-2022 | Glioma | Primary research

Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma

Authors: Xingbo Cheng, Zhishuai Ren, Zhendong Liu, Xiang Sun, Rongjun Qian, Chen Cao, Binfeng Liu, Jialin Wang, Hongbo Wang, Yuqi Guo, Yanzheng Gao

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Background

Cysteine cathepsin C encoded by the CTSC gene is an important member of the cysteine cathepsin family that plays a key role regulation of many types of tumors. However, whether CTSC is involved in the pathological process of glioma has not yet been reported. We comprehensively analyzed data from multiple databases and for the first time revealed a role and specific mechanism of action of CTSC in glioma, identifying it as a novel and efficient biomarker for the diagnosis and treatment of this brain tumor.

Methods

The expression of CTSC in glioma and its relationship with clinical characteristics and prognosis of patients with glioma were analyzed at different levels by using clinical sample information from several databases. CTSC expression levels in glioma and normal brain tissues, as well as in glioma cells and normal brain cells, was validated by real-time quantitative polymerase chain reaction (RT-qPCR). Gene set enrichment analysis (GSEA) was used to reveal the signaling pathways that CTSC may participate in. The connectivity map was used to reveal small molecules that may inhibit CTSC expression in glioma, and the putative effect of these compounds was verified by RT-qPCR.

Results

Our analyses showed that the expression of CTSC in glioma was higher than that in non-cancerous cells. GSEA showed that CTSC expression may regulate the malignant development of glioma through Toll-like receptor signaling pathways, pathways in cancer, and extracellular matrix receptor interaction signaling pathways. And we proved piperlongumine and scopoletin could inhibit CTSC expression in glioma cells.

Conclusions

CTSC may serve as an efficient molecular target for the diagnosis and therapy of glioma, thereby improving the poor prognosis of patients with glioma.
Appendix
Available only for authorised users
Literature
1.
Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMed
2.
Ostrom Q, Cote D, Ascha M, Kruchko C, Barnholtz-Sloan J. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4(9):1254–62.PubMedPubMedCentral
3.
Nagarajan R, Costello J. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009;19(3):188–97.PubMed
4.
Jhaveri N, Chen T, Hofman F. Tumor vasculature and glioma stem cells: contributions to glioma progression. Cancer Lett. 2016;380(2):545–51.PubMed
5.
Kalinina J, Peng J, Ritchie J, Van Meir E. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol. 2011;13(9):926–42.PubMedPubMedCentral
6.
7.
Berghoff A, Stefanits H, Heinzl H, Preusser M. Clinical neuropathology practice news 4-2012: levels of evidence for brain tumor biomarkers. Clin Neuropathol. 2012;31(4):206–9.PubMedPubMedCentral
8.
Patel M, Vogelbaum M, Barnett G, Jalali R, Ahluwalia M. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs. 2012;21(9):1247–66.PubMed
9.
Gupta K, Salunke P. Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol. 2012;138(12):1971–81.PubMed
10.
Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–50.PubMed
11.
Kafka A, Bačić M, Tomas D, Žarković K, Bukovac A, Njirić N, et al. Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation. J Cell Mol Med. 2019;23(1):641–55.PubMed
12.
Olson O, Joyce J. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15(12):712–29.PubMed
13.
Breznik B, Limback C, Porcnik A, Blejec A, Krajnc M, Bosnjak R, et al. Localization patterns of cathepsins K and X and their predictive value in glioblastoma. Radiol Oncol. 2018;52(4):433–42.PubMedPubMedCentral
14.
Kenig S, Frangež R, Pucer A, Lah T. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis. 2011;16(7):671–82.PubMed
15.
Lankelma J, Voorend D, Barwari T, Koetsveld J, Van der Spek A, De Porto A, et al. Cathepsin L, target in cancer treatment? Life Sci. 2010;86:225–33.PubMed
16.
Gole B, Huszthy P, Popović M, Jeruc J, Ardebili Y, Bjerkvig R, et al. The regulation of cysteine cathepsins and cystatins in human gliomas. Int J Cancer. 2012;131(8):1779–89.PubMed
17.
Kenig S, Frangež R, Pucer A, Lah T. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis: an international journal on programmed cell death. 2011;16(7):671–82.
18.
Lankelma J, Voorend D, Barwari T, Koetsveld J, Van der Spek A, De Porto A, et al. Cathepsin L, target in cancer treatment? Life sciences. 2010;86:225–33.PubMed
19.
Flannery T, McQuaid S, McGoohan C, McConnell R, McGregor G, Mirakhur M, et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—a pilot study. Int J Cancer. 2006;119(4):854–60.PubMed
20.
Khaket T, Singh M, Khan I, Bhardwaj M, Kang S. Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells. Cell Signal. 2018;46:92–102.PubMed
21.
Folkerts H, Hilgendorf S, Vellenga E, Bremer E, Wiersma V. The multifaceted role of autophagy in cancer and the microenvironment. Med Res Rev. 2019;39(2):517–60.PubMed
22.
Zhang G, Yue X, Li S. Cathepsin C. Interacts with TNF-α/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer research treatment: official journal of Korean Cancer Association. 2020;52(1):10–23.
23.
Ikenoue T, Hong S, Inoki K. Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol. 2009;452:165–80.PubMed
24.
Xiao G, Zhang X, Zhang X, Chen Y, Xia Z, Cao H, et al. Aging-related genes are potential prognostic biomarkers for patients with gliomas. Aging. 2021;13(9):13239–63.PubMedPubMedCentral
25.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.PubMedPubMedCentral
26.
Barrett T, Troup D, Wilhite S, Ledoux P, Evangelista C, Kim I, et al. NCBI GEO: archive for functional genomics data sets--10 years on. Nucleic Acids Res. 2011;39:D1005–10.PubMed
27.
Thul P, Lindskog C. The human protein atlas: A spatial map of the human proteome. Protein Sci. 2018;27(1):233–44.PubMed
28.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.PubMedPubMedCentral
29.
Lamb J, Crawford E, Peck D, Modell J, Blat I, Wrobel M, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York). 2006; 313(5795):pp. 1929–35.
30.
Joyce J, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle. 2004;3(12):1516–619.PubMed
31.
Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20(5):543–56.PubMedPubMedCentral
32.
Ruffell B, Affara N, Cottone L, Junankar S, Johansson M, DeNardo D, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev. 2013;27(19):2086–98.PubMedPubMedCentral
33.
Chai R, Zhang K, Chang Y, Wu F, Liu Y, Zhao Z, et al. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019;40(10):1229–39.PubMed
34.
Zhang H, Tao J, Sheng L, Hu X, Rong R, Xu M, et al. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. Onco Targets Ther. 2016;9:1801–12.PubMedPubMedCentral
35.
Xu Y, Liu H, Liu S, Wang Y, Xie J, Stinchcombe T, et al. Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer. 2018;143(10):2400–8.PubMedPubMedCentral
36.
37.
Matijevic Glavan T, Cipak Gasparovic A, Vérillaud B, Busson P, Pavelic J. Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF. Mol Carcinog. 2017;56(4):1214–26.PubMed
38.
39.
Veyrat M, Durand S, Classe M, Glavan T, Oker N, Kapetanakis N, et al. Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells. Oncotarget. 2016;7(50):82580–93.PubMedPubMedCentral
40.
Dong X, Tamura K, Kobayashi D, Ando N, Sumita K, Maehara T. LAPTM4B-35 is a novel prognostic factor for glioblastoma. J Neurooncol. 2017;132(2):295–303.PubMed
41.
Ookawa S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Ohtaki S, et al. Digital polymerase chain reaction quantification of SERPINA1 predicts prognosis in high-grade glioma. World Neurosurg. 2018;111:e783-9.PubMed
42.
Kee H, Ahn K, Choi K, Won Song J, Heo T, Jung S, et al. Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma. FEBS Lett. 2004;569:307–16.PubMed
43.
Rodrigues Silva D, Baroni S, Svidzinski A, Bersani-Amado C, Cortez D. Anti-inflammatory activity of the extract, fractions and amides from the leaves of Piper ovatum Vahl (Piperaceae). J Ethnopharmacol. 2008;116(3):569–73.PubMed
44.
Bezerra D, Pessoa C, de Moraes M, Saker-Neto N, Silveira E, Costa-Lotufo L. Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 2013;48(3):453–63.PubMed
45.
Kim T, Song J, Kim S, Parikh A, Mo X, Palanichamy K, et al. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol. 2014;16(10):1354–64.PubMedPubMedCentral
46.
47.
Liu J, Pan F, Li L, Liu Q, Chen Y, Xiong X, et al. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun. 2013;437(1):87–93.PubMed
48.
Pei S, Minhajuddin M, Callahan K, Balys M, Ashton J, Neering S, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem. 2013;288(47):33542–58.PubMedPubMedCentral
49.
Tian Q, Wang L, Sun X, Zeng F, Pan Q, Xue M. Scopoletin exerts anticancer effects on human cervical cancer cell lines by triggering apoptosis, cell cycle arrest, inhibition of cell invasion and PI3K/AKT signalling pathway. J BUON. 2019;24(3):997–1002.PubMed
Metadata
Title
Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma
Authors
Xingbo Cheng
Zhishuai Ren
Zhendong Liu
Xiang Sun
Rongjun Qian
Chen Cao
Binfeng Liu
Jialin Wang
Hongbo Wang
Yuqi Guo
Yanzheng Gao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02417-6

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Mini review

Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer

Research

Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire

Primary research

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study

Research

Regulation of mitochondrial complex III activity and assembly by TRAP1 in cancer cells

Research

Oleic acid from cancer-associated fibroblast promotes cancer cell stemness by stearoyl-CoA desaturase under glucose-deficient condition

Primary research

SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits